BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38349410)

  • 1. Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells.
    Sueangoen N; Grove H; Chuangchot N; Prasopsiri J; Rungrotmongkol T; Sanachai K; Darai N; Thongchot S; Suriyaphol P; Sa-Nguanraksa D; Thuwajit P; Yenchitsomanus PT; Thuwajit C
    Cancer Immunol Immunother; 2024 Feb; 73(3):43. PubMed ID: 38349410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigens elicit T cell responses in breast cancer.
    Morisaki T; Kubo M; Umebayashi M; Yew PY; Yoshimura S; Park JH; Kiyotani K; Kai M; Yamada M; Oda Y; Nakamura Y; Morisaki T; Nakamura M
    Sci Rep; 2021 Jun; 11(1):13590. PubMed ID: 34193879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.
    Panya A; Thepmalee C; Sawasdee N; Saengmuang S; Luangwattananun P; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115827. PubMed ID: 37939617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
    Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
    Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Identification of neoantigens and development of antigen-specific immunotherapy].
    Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
    Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database.
    Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
    Oncol Lett; 2020 Nov; 20(5):123. PubMed ID: 32934692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
    Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
    Front Immunol; 2020; 11():576603. PubMed ID: 33329543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
    Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
    Lazdun Y; Si H; Creasy T; Ranade K; Higgs BW; Streicher K; Durham NM
    Mol Cancer Res; 2021 Mar; 19(3):498-506. PubMed ID: 33257508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.
    Zhang W; Yin Q; Huang H; Lu J; Qin H; Chen S; Zhang W; Su X; Sun W; Dong Y; Li Q
    Front Oncol; 2021; 11():628456. PubMed ID: 33928024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
    Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.